Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TNFSF10
REST API REST API
Homo sapiens
TNFSF10 is differentially expressed in 334 experiments: 160 organism parts: prostate, trachea, ... (158 more);, 223 disease states: normal, prostate carcinoma, ... (221 more);, 112 cell types 460 cell lines 62 compound treatments and 76 other conditions.
Synonyms CD253, Apo-2L, TL2, TRAIL
Orthologs Tnfsf10 (Mus musculus)   tnfsf10l2 (Danio rerio)   E1BE56_BOVIN (Bos taurus)   F1NF17_CHICK (Gallus gallus)   Tnfsf10 (Rattus norvegicus)   TNFSF10 (Xenopus laevis)   B4XH66_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, apoptosis, extracellular space, membrane, tumor necrosis factor receptor binding, metal ion binding, activation of caspase activity, extracellular region, receptor binding, cell-cell signaling, cytokine activity, soluble fraction, induction of apoptosis, integral to plasma membrane, immune response, signal transduction, positive regulation of I-kappaB kinase/NF-kappaB cascade, activation of pro-apoptotic gene products, induction of apoptosis by extracellular signals
InterPro Term TNF_family, TNF_ligand_10/11
UniProt Accession A1Y9B3, P50591, Q6IBA9, Q6JSD9
Search EB-eye ENSG00000121858
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
PC3
2
E-GEOD-5258, E-MEXP-2034
MCF-10A
2
E-TABM-420, E-GEOD-14990
H1648
2
E-GEOD-4342, E-MTAB-62
Daudi
2
E-GEOD-96, E-MTAB-37
MDA468
2
E-MEXP-440, E-MTAB-62
454 more value(s).


Cell type

studied in E-GEOD-500, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-21750, ... (51 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
E-GEOD-16190, E-GEOD-6740
testis - germ cell
2
E-AFMX-5, E-TABM-145
whole blood
2
E-MTAB-25, E-GEOD-3026
hematopoietic progenitor cells
1
E-MEXP-70
mesothelial cells
1
E-GEOD-21750
106 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-MEXP-2280, ... (69 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-2514
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
adenocarcinoma
2
E-MEXP-1331, E-MTAB-37
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-MTAB-62, E-MTAB-37
217 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5542, E-TABM-782, E-GEOD-5824, E-GEOD-4748, ... (38 experiments)

Factor Value U/D Experiments
none
5
12
E-MEXP-1958, E-GEOD-20719, E-GEOD-6907, E-TABM-782, E-GEOD-4668, ... (17 experiments)
lipopolysaccharide
1
2
E-MEXP-1958, E-GEOD-4748, E-TABM-868
5-fluorouridine
1
E-GEOD-995
BCR/ABL1
1
E-GEOD-15811
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
DMSO
1
E-MEXP-1561
56 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-2666, ... (9 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-2509, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7578, E-GEOD-17385, E-MTAB-108, E-GEOD-361

Genotype
studied in E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-GEOD-18005, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-6532

Processing time: 0.263 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM